U.S. pharmaceutical company Pfizer is preparing to urgently apply for its covid-19 vaccine, company president Albert Bourla said Tuesday.
The statement was made at a forum hosted by The New York Times and STAT News after Bourla, his company and German partner BioNTech announced on November 9 that the vaccine is more than 90% effective.
“We are very close to applying for an emergency permit,” the head of the pharmaceutical company said, not wanting to give a specific date.
According to Bourla, Pfizer has already collected the safety data required by health authorities, and manufacturers must monitor half of the people who were vaccinated in phase 3 trials for at least two months.
Nearly 44,000 people took part in the tests, which began in July, and according to the company, the vaccine was more than 90% effective in the participants without any previous evidence of infection.
Following an announcement by Pfizer and BioNTech, the modern biotechnology company on Monday announced the results of its vaccine project studies, which indicate an efficiency of about 94%.
Bourla, at the STAT News forum, was pleased to learn that there is another successful vaccine and expressed confidence that there will be even more, as global demand will outweigh the potential of any company.
When they announced the success of the tests, Pfizer and BioNTech stated that they expect to generate 50 million doses and 1.3 billion doses by 2021 this year.